Trade of the Day: No. 1 Biotech Pick GILD Gilead on Sale

Gilead Sciences, Inc. (GILD) — I last covered GILD stock in the Trade of the Day on June 16. Since then, shares have fallen nearly 4%. Does the decline shake my confidence in this biotechnology giant? Absolutely not. GILD stock remains my No. 1 pick in the sector.
Capital IQ is confident that Gilead will maintain its dominant market position in the treatment of hepatitis C and continue to show significant sales growth despite competition. Its analysts put Gilead’s market share at 90% and believe it has only served an estimated 4% of the 6.6 million people with hepatitis C in the United States and some European countries. While competition is expected to increase, they note that Gilead’s Harvoni is physicians’ preferred treatment due to its ease of  (more)